PTC Therapeutics, Inc. Total Contract Liability
PTC Therapeutics, Inc. (PTCT) had Total Contract Liability of $200.00 thousand as of 2023-03-31, per its 10-Q filed 2023-04-27.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2023-04-27
- 2023-03-31: Contract with Customer, Liability $200.00K.
- 2022-12-31: Contract with Customer, Liability $1.40M.
- 2022-09-30: Contract with Customer, Liability $0.00.
- 2022-06-30: Contract with Customer, Liability $0.00.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2023-03-31 | $200.00K 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $1.40M 10-Q · filed 2023-04-27 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $0.00 10-K · filed 2023-02-21 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-10-28 | |
| 2021-03-31 | $1.90M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $4.20M 10-K · filed 2022-02-22 | |
| 2020-09-30 | $6.00M 10-Q · filed 2020-10-29 | |
| 2019-12-31 | $11.70M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $14.31M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $15.80M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $14.35M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $12.90M 10-K · filed 2020-03-02 | $12.94M 10-K · filed 2019-03-01 |
| 2018-09-30 | $12.66M 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $10.54M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $9.30M 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $11.89M 10-Q · filed 2019-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |